Biogen wins patent challenge to key multiple sclerosis drug
A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug Tecfidera, putting off the early launch of a generic version by Mylan and sending shares of Biogen surging.
Mylan, the generic drug maker, had filed an inter partes review seeking to overturn the last remaining patent on Tecfidera, Biogen’s most important multiple sclerosis drug. That patent was not set to expire until 2028.
Read Original Article: Biogen wins patent challenge to key multiple sclerosis drug »
